Business
AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime
About this update from Tectonic Therapeutic, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will present safety data from its clinical trials in Fabry disease and Gaucher disease type 1 at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) on Nov. 21-23, 2021, in Sydney, Australia.\n\nClinical and preclinical data from the company’s pipeline of lysosomal disorder programs will be included in one oral presentation and two poster presentations.\n\nAdditionally, AVROBIO will sponsor a symposium on “Advancing the patient experience during ex vivo lentiviral gene therapy for lysosomal disorders,” chaired by Prof. Rob Wynn (University of Manchester, UK). The symposium includes an overview of the lentiviral gene therapy approach in lysosomal disorders and an expert panel, featuring Dr. Mark Thomas (Royal Perth Hospital, WA, AUS), Dr. Kathy Nicholls (Royal Melbourne Hospital, VIC, AUS) and Dr. Ben Carnley (Royal Perth Hospital, WA, AUS), who will discuss managing the patient experience with ex vivo lentiviral gene therapy based on their involvement in the FAB-GT clinical trial.\n\nThe presentations are listed below, and the full preliminary program is available online at the ICIEM website.\n\nORAL PRESENTATIONS:\n\n“Clinical data trends from Phase 1 and Phase 2 studies for AVR-RD-01, an investigational lentiviral gene therapy for Fabry disease”\nTuesday, Nov. 23, 2021, 11:45 a.m. AEDT\n\nMark Thomas, M.D., principal investigator of the AVROBIO-sponsored FAB-GT Phase 2 trial of AVR-RD-01, an investigational gene therapy for Fabry disease, Nephrologist at the Department of Nephrology, Royal Perth Hospital and clinical professor at the University of Western Australia Medical School, will present safety data from the patients in the Phase 1 and Phase 2 clinical trials.\n\nRECORDED POSTER PRESENTATIONS:\n\n“The Guard1 clinical trial: A first in-human, open-label, multinational Phase 1/2 study of AVR-RD-02 ex vivo lentiviral vector, autologous gene therapy for Gaucher disease”\n\nChris Mason, M.D., Ph.D., chief scientific officer, AVROBIO\n\n“Long-term outcomes of brain-targeted stem cell gene therapy for Mucopolysaccharidosis type II in a pre-clinical MPSII mouse model”\n\nBrian Bigger, Ph.D., professor, Univers...